Standardization of clinical trials subject ID schematics: A portfolio-wide model to enhance data integrity and regulatory compliance

Abstract

Background

Subject identification is a cornerstone of data integrity and regulatory compliance in clinical trials. Legacy, study-specific subject ID conventions may cause risk of duplication, hinder traceability of rescreened participants, and complicate regulatory submissions—particularly in large global portfolios where multiple trials for similar disease areas from the same sponsor are handled by the same site and the same PI. Regulatory guidance from the U.S. Food and Drug Administration (FDA Technical Conformance Guide), the Clinical Data Interchange Standards Consortium (CDISC SDTM), and ICH E6(R2) mandates unique subject traceability throughout a study's lifecycle.

Aim

This paper introduces, validates, and evaluates a standardized subject-identification schema designed to eliminate risk of duplication, ensure traceable rescreening, and harmonize subject IDs across an organization's clinical portfolio while aligning with global regulatory requirements.

Methods

A cross-functional Biogen team spanning Global Clinical Operations, Data Systems, IT, Clinical Supply, with inputs from external partners (CROs and IXRT vendors) designed a new schema (SSSS-PYZ-XXXA). The structure encodes site (SSSS), program (P), phase (Y), study sequence (Z), subject number (XXX), and screening attempt (A). Validation comprised retrospective pressure testing with historical data, pilot implementation in active trials, and benchmarking against CDISC SDTM and FDA TCG standards.

Results

The standardized schema eliminated subject-ID overlap across parallel studies, enabled seamless rescreen tracking without creating multiple USUBJIDs, and proved compatible with EDC, CTMS, IXRT, and LIMS systems. As of 2025, the schema had been adopted in at least 59 new trials across multiple therapeutic areas, improving SDTM mapping and regulatory preparedness.

Conclusion

A portfolio-wide standardized subject-ID schema provides a sustainable, scalable framework that strengthens data integrity, streamlines operations, and enhances regulatory compliance across clinical development programs.

1. Introduction

Subject identification is a foundational element of data integrity and regulatory compliance in clinical trials. The assignment and management of unique subject identifiers (IDs) underpin the traceability of participant data throughout the lifecycle of a study and across complex clinical trial portfolios. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonization (ICH), mandate that each subject must be uniquely traceable in all clinical trial submissions, as outlined in the FDA Technical Conformance Guide and the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) standards [[1], [2], [3]]– (see Fig. 1).

Fig. 1.

Various Schema Options Considered and Rejected

Flowchart illustrating subject-ID options evaluated and rejected or selected based on the predefined criteria.

Despite these requirements, the prevailing industry practice has been to use study- or program-specific conventions for subject IDs. This approach has led to several persistent challenges, including the risk of duplication of subject identifiers in studies conducted at the same site, the inability to continuously track rescreened subjects or those rolling over into extension studies, and fragmentation at the portfolio level due to differing conventions among contract research organizations (CROs) and vendors. These deficiencies not only undermine data quality and operational efficiency but also complicate regulatory review, potentially delaying drug development and approval [1,2,4].

The complexity of modern clinical trial portfolios—characterized by global reach, adaptive designs, and increasing data volume—further amplifies the need for harmonized subject identification. Recent regulatory initiatives, such as the ICH M11 guideline on clinical electronic structured protocols and the EMA guideline on computerised systems and electronic data in clinical trials, emphasize the importance of standardized data exchange and traceability across studies [3,5]. In parallel, industry standards such as CDISC SDTM and emerging best practices for subject-ID assignment and tracking have highlighted the operational and compliance benefits of a unified approach [2,5].

Recognizing these challenges, our organization undertook a cross-functional initiative to design, validate, and implement a portfolio-wide standardized subject-ID schema. The aim was to eliminate duplication, enable traceable rescreening, and synchronize subject identification across all studies while ensuring compatibility with regulatory requirements and clinical data systems. This paper introduces the rationale, design, and impact of the new schema, benchmarking it against industry standards and regulatory guidance, and demonstrating its scalability and effectiveness across diverse therapeutic areas [4,6].

2. Methods

2.1. Study design and evaluation framework

This work represents an organizational quality improvement initiative with both retrospective and prospective evaluation components. The initiative focused on the design, implementation, and portfolio-wide deployment of a standardized subject identifier schema, followed by evaluation of operational performance, data integrity, and regulatory traceability outcomes using de-identified operational datasets. Retrospective analyses assessed legacy subject identifier practices, while prospective monitoring evaluated outcomes following implementation of the standardized schema.

The implementation and evaluation of the standardized subject identifier schema were conducted over a defined multi-year period spanning November 2020 to November 2025. Initial schema design, pilot testing, and operational rollout were completed over approximately eight months; however, outcome evaluation intentionally extended beyond initial implementation to assess sustained adoption and portfolio-level impact over time.

For comparative purposes, studies initiated prior to standardized schema deployment were designated as the pre-implementation period, while studies initiated following portfolio-wide rollout were designated as the post-implementation period. Evaluation outcomes were assessed descriptively, consistent with the objective of characterizing implementation impact rather than testing predefined statistical hypotheses.

Statistical testing was not performed because the data analyzed were operational and implementation-focused, generated through a quality improvement initiative rather than prospectively designed for inferential or hypothesis-driven analysis.

2.2. Study design and team structure

This initiative was conducted as a cross-functional project within Biogen, involving representatives from Global Clinical Operations, Data Systems, Information Technology, Clinical Supply, and several external partners, including multiple contract research organizations (CROs) as well as several interactive response technology (IXRT) vendors. The objective was to design, validate, and implement a standardized subject-identification (ID) schema that would address persistent data-integrity and operational challenges observed across the sponsor's clinical-trial portfolio [7].

A collaborative governance model was established to ensure that the schema design reflected operational requirements across multiple systems – electronic data capture (EDC), clinical-trial management systems (CTMS), IXRT, and laboratory information management systems (LIMS). A portfolio-level data-integrity board provided steering oversight to align the implementation with regulatory guidance and internal quality-management frameworks [7,8].

2.3. Schema evolution and design principles

A comprehensive review of legacy subject-ID conventions (SSS-XXX) revealed that identifiers were often study-specific and lacked built-in mechanisms to track rescreened participants or those continuing into extension studies. This fragmentation led to duplication, inconsistencies, and additional manual oversight during regulatory submission [4,7].

To address these limitations, the team developed a new schema expressed as SSSS-PYZ-XXXA, where:

• •SSSS = Site number (numeric, country-specific)
• •P = Program identifier (alphabetic)
• •Y = Study phase (numeric)
• •Z = Sequence of study within the program/phase (alphabetic)
• •XXX = Sequential subject number within the study (numeric)
• •A = Screening/rescreening identifier (alphabetic; flips A–B–C for multiple attempts)

This structure ensured uniqueness, traceability, and compliance with international data-submission requirements outlined in the FDA Technical Conformance Guide [1] and CDISC SDTM Implementation Guide [2]. The design also considered forward compatibility with the forthcoming ICH M11 Structured Protocol Template, which promotes standardized parameterization of clinical-protocol data [6].

2.3.1. Evaluation of alternative subject ID schemas

During schema development, multiple formats were proposed and evaluated by a cross-functional team. The goal was to enable subject traceability across studies while ensuring compatibility with systems like Interactive Response Technology (IRT), Electronic Data Capture (EDC) and labeling platforms.

2.3.2. Key evaluation criteria

• •Cross-study traceability
• •System compatibility (e.g., character limits)
• •Operational feasibility
• •Scalability across programs and therapeutic areas

2.3.3. Final schema decision

The team selected a modified version of Option B:

• •SSSS-PYZ-XXXA: Site, Program, Phase, Sequence, Subject, Attempt
• •Centralized assignment via master Excel tracker
• •Automated rescreening identifier via IRT

This format balanced traceability, system compatibility, and operational feasibility. While it introduced a new administrative step, the benefits in data integrity and regulatory alignment justified the effort.

2.4. Validation and usability testing

As part of validation and usability testing, evaluation focused on two complementary dimensions: study-level adoption and operational consistency. Adoption was assessed by examining uptake of the standardized subject identifier schema across eligible studies initiated during the evaluation period, while operational consistency was assessed through structured cross-system checks confirming alignment of subject identifiers across the centralized registry, electronic data capture (EDC), and clinical trial management system (CTMS).

The standardized schema underwent a three-stage validation plan combining retrospective pressure-testing, pilot implementation, and stakeholder review [7].

• 1.Retrospective Pressure-Testing: Historical datasets from multiple studies were recoded using the proposed schema to evaluate uniqueness, re-screen traceability, and system interoperability.
• 2.Pilot Implementation: The schema was introduced in live trials across different therapeutic areas to verify compatibility with EDC, CTMS, IXRT, and LIMS platforms.
• 3.Stakeholder Feedback: Operational teams and CRO partners provided structured feedback on workflow adaptation, exception handling, and transition planning for legacy studies.

Testing confirmed that the schema effectively removed subject-ID overlap, maintained traceability for rescreened participants, and was operationally feasible within existing system architectures [4,7].

2.5. Benchmarking against industry standards

The finalized schema was benchmarked against prevailing regulatory and industry frameworks to ensure global alignment:

• •CDISC SDTM Model: Ensured interoperability for study-data tabulations and facilitated automated mapping of the variable USUBJID (Unique Subject Identifier) [2].
• •FDA Technical Conformance Guide: Validated adherence to FDA submission expectations for unique subject traceability and reproducible datasets [1].
• •ICH E6(R2) Good Clinical Practice: Confirmed compliance with traceability and data-integrity principles [3].
• •EMA Guideline on Computerised Systems and Electronic Data in Clinical Trials: Ensured system validation and audit-trail robustness in alignment with EU GCP requirements [5].

This benchmarking demonstrated that the standardized schema not only met but exceeded minimal regulatory expectations, providing a scalable model suitable for integration into industry data-standards initiatives such as CDISC and PhUSE [4,9].

2.6. Implementation and governance

A master subject-ID registry was established within the sponsor's central data warehouse to prevent duplication across studies and maintain portfolio-wide integrity. Risk mitigation controls were incorporated into the operational governance model. The centralized subject-ID registry was maintained with role-based access controls, audit trails documenting identifier creation and modification, and controlled versioning of registry files. These measures were intended to support traceability, accountability, and recovery in the event of process deviations or human error.

Governance policies were defined for:

• •Schema updates: Handling future protocol-design changes or regulatory revisions.
• •Exception management: Documenting deviations for legacy systems or extension studies.
• •Training and documentation: Mandatory briefings for site personnel, CROs, and vendors.

Operational rollout was accompanied by user manuals, validation templates, and cross-functional workshops to ensure consistent adoption [4,7,9] (see Fig. 2).

Fig. 2.

Subject-ID assignment internal operational process flow

Flowchart illustrating subject-ID assignment requested from the internal departments all the way to CRO for seamless allocation using master-sheet.

2.7. Ethical and data-integrity considerations

Although this initiative did not involve direct patient intervention or the use of identifiable personal data, all processes adhered to ethical data-handling principles under ICH E6(R2) Good Clinical Practice and GDPR requirements for pseudonymization and traceability [3,10]. No additional ethical approvals were required because the schema was developed using de-identified operational datasets.

3. Results

3.1. Adoption and implementation metrics

Since the introduction of the standardized subject-ID schema (SSSS-PYZ-XXXA), adoption has expanded rapidly across the sponsor's clinical-trial portfolio. As of 2025, the schema had been deployed in over 50 new trials encompassing neurology, immunology, and rare-disease programs, while 16 legacy programs still relied on the former SSS-XXX format due to system dependencies or ongoing extension studies [11].

To coordinate global implementation, a centralized Excel-based master registry was established to ensure unique identifiers across all sites and protocols. Periodic compliance audits demonstrated a >99 % match between assigned IDs and entries in EDC and CTMS systems [12] (see Table 1).

Table 1.

Various schema options considered and rejected.

Option	Format Example	Reason for Rejection
A	New site ID per study	No site continuity; tracking across studies impossible
B	Shared protocol ID	Limited scalability (10 protocols, 100 subjects); IRT-only
C	9-digit with protocol prefix	Too long (12+ characters); label and system risks
D	SSS-PXXXA/SSS-PP-XXXA	Limited protocol depth; not scalable
E	SSS-1A-XXXA	Complex parsing; phase/study logic unclear

Table 2 summarizes portfolio-wide adoption across therapeutic areas and schema types.

Table 2.

Adoption of standardized versus legacy subject-ID schema across the sponsor portfolio.

Schema Type	Number of Trials	Therapeutic Areas Covered	Portfolio Consistency	Regulatory Alignment
Legacy (SSS-XXX)	16 (Legacy studies)	3	Low	Partial
Standardized (SSSS-PYZ-XXXA)	50+	7 +	High	Full

Portfolio-level comparison of the legacy and standardized subject-ID formats implemented from 2021 to 2025—adoption rate measured through master sheet registry-tracking.

3.2. Operational outcomes

Implementation of the standardized schema produced measurable improvements in data-management efficiency and subject traceability. While maintaining a central master file introduced minor operational overhead, it yielded significant gains in preventing duplication and ensuring continuous follow-up [7,11].

The new format eliminated subject-ID overlap across concurrent studies. It allowed participants who were rescreened or rolled into extension trials to retain a single, unique USUBJID, ensuring longitudinal integrity across datasets. Automated reconciliation within CTMS and IXRT platforms confirmed one-to-one subject mapping without manual correction in >95 % of cases [7,12].

Quality-assurance testing verified system compatibility with major EDC vendors and IXRT platforms [13].

3.3. Regulatory outcomes

The standardized schema significantly improved regulatory preparedness by facilitating direct alignment with CDISC SDTM mapping conventions and meeting FDA data-traceability expectations [1,2,14].

Regulatory outcomes described in this section reflect investigational clinical trial submissions for new drug development programs operationally managed by Global Clinical Operations, and do not include post-marketing, medical, or lifecycle management submissions.

During pilot submissions, successful data import into the FDA Study Data Validator tool was observed without subject-ID conflicts, demonstrating improved technical validation behavior, consistent with published FDA and EMA validation guidance [14,15].

Adoption also enhanced readiness for EMA and MHRA electronic submissions, supporting automated cross-study linkage and traceability [5,15].

Formal quantification of the number of FDA and EMA submissions evaluated was not performed as part of this work. Regulatory observations described in this section are based on internal assessments of submission readiness and technical validation behavior during pilot and early adoption activities, rather than a systematic review of health-authority evaluations.

While formal health-authority review metrics were not collected, internal submission teams observed fewer data clarification iterations and reduced rework during submission preparation, attributable to improved subject traceability and standardized identifier structure.

The standardized schema demonstrates complete SDTM alignment and a reduction in technical validation findings during regulatory data review. Regulatory feedback did not explicitly reference subject identifier structure; observed improvements were reflected through validation behavior and alignment with published FDA and EMA data standards guidance.

3.4. Comparative analysis

Direct comparison between the legacy SSS-XXX and standardized SSSS-PYZ-XXXA formats demonstrates the latter's superiority in operational efficiency, traceability, and regulatory reliability. Under the legacy system, rescreened subjects often generated duplicate USUBJIDs, fragmenting longitudinal data and requiring manual reconciliation during submission [4,7].

The standardized schema resolved these deficiencies by embedding rescreen-tracking logic and cross-study lineage within a single identifier [7,11].

Feedback from CROs and internal study teams confirmed that no subject-tracking discrepancies were reported following implementation, along with improved confidence in cross system reporting [12,13]. These outcomes underscore the schema's potential for broader industry adoption and incorporation into regulatory-submission best practices [15].

4. Discussion

The implementation of a portfolio-wide standardized subject-identification (ID) schema represents a significant advancement in clinical-trial data management and regulatory compliance. The transition from the legacy SSS-XXX format to the SSSS-PYZ-XXXA structure directly addressed persistent challenges related to data duplication, fragmented subject histories, and inconsistent identification across contract research organizations (CROs) and vendors [4,7,11].

4.1. Operational impact

The operational transformation introduced by the new schema—particularly the establishment of a central master registry-has been significant. As shown in Table 2, portfolio consistency increased substantially once a unified registry and governance framework were adopted. The centralized subject-ID assignment added a modest layer of administrative effort but delivered measurable gains in data integrity, traceability, and regulatory preparedness [7,11,12].

By enforcing unique identifiers across studies and maintaining traceability of rescreened and rollover subjects, the schema virtually eliminated the need for manual reconciliation between study databases. Audit results demonstrated a >99 % accuracy rate for subject-ID alignment between the electronic data-capture (EDC) and clinical-trial-management systems [12]. These improvements echo prior recommendations from the PhUSE Data Transparency Working Group and CDISC SDTM Implementation Guide, which emphasize central data stewardship as a quality-by-design principle [2,9,16].

Implementation considerations for standardized subject identifier schemas may vary based on sponsor size and portfolio complexity. Large pharmaceutical organizations typically manage numerous concurrent studies across multiple programs and geographies, increasing the risk of subject identifier duplication and fragmentation and thereby amplifying the value of centralized governance. Mid-size pharmaceutical organizations may operate with fewer parallel studies and simpler operational structures; however, early adoption of standardized identifier conventions can help prevent future fragmentation as pipelines expand. In these settings, similar principles can be applied using proportionate governance models while preserving core objectives of subject uniqueness, traceability, and regulatory alignment.

In addition to organizational scale, therapeutic-area characteristics may further influence the value of standardized subject identification. Portfolios targeting disease areas that frequently involve the same investigative sites and principal investigators—such as rare diseases or specialized therapeutic indications—may face heightened risk of subject overlap across studies. In such contexts, adoption of a standardized subject identifier framework may provide particular benefit by reducing duplication risk and supporting longitudinal subject traceability.

4.2. Regulatory alignment

The schema's structure aligns closely with several key international frameworks, including the FDA Technical Conformance Guide, CDISC SDTM, ICH E6(R2) Good Clinical Practice, and EMA Guideline on Computerized Systems [[1], [2], [3], [4], [5]]. This alignment ensures that each participant is uniquely traceable throughout the data lifecycle, supporting both ethical and scientific accountability.

As summarized in Table 3, the new schema achieved full SDTM mapping automation and eliminated subject-traceability conflicts in regulatory submissions. During pilot reviews, the FDA Study Data Validator reported fewer import errors and significantly faster validation processing [14]. This mirrors earlier observations by Jain [4], who demonstrated that systematic identifier design contributes directly to regulatory efficiency.

Table 3.

Regulatory performance comparison of legacy and standardized subject-ID schemas.

Outcome	Legacy Schema	Standardized Schema
Unique Subject Traceability	Partial	Full
SDTM Mapping	Manual	Automated
FDA Submission Readiness	Variable	Consistent

Beyond meeting current requirements, the schema anticipates forthcoming ICH M11 standards that promote structured-protocol harmonization and machine-readable metadata [6,17]. It thus positions the sponsor for seamless adaptation to evolving digital-submission ecosystems such as the FDA's NextGen Study Data Review Tool [18].

4.3. Benchmarking and industry context

Benchmarking against industry norms confirms the superiority of the standardized model. Fig. 3 illustrates its logical encoding hierarchy, which eliminates redundancy and enables interoperability with diverse data systems. Fig. 4 outlines the end-to-end assignment and verification workflow, reflecting the “traceability chain” principle now embedded in many GCP interpretations [3,5,15].

Fig. 3.

Structure of the standardized subject-ID schema (SSSS-PYZ-XXXA)

Caption: Hierarchical representation of schema components:

SSSS = Site number (numeric, country-specific); P = Program identifier (alphabetic); Y = Study phase (numeric); Z = Sequence within program/phase (alphabetic); XXX = Sequential subject number (numeric); A = Screening/rescreening identifier (alphabetic).

The design ensures unique and traceable identifiers across all studies.

Fig. 4.

Subject-ID assignment and rescreen-tracking process flow

Flowchart illustrating subject-ID assignment from site enrollment through rescreening and rollover phases. The process includes registry validation, duplication check, rescreen flagging (A → B → C), and synchronization with EDC and CTMS databases.

Feedback from CRO partners indicated that no subject-tracking discrepancies were reported once the schema was introduced [12,13]. These results are consistent with best-practice models published by PhUSE (2021) and Clinical Trials Transformation Initiative (CTTI 2022), both advocating harmonized identifier management to strengthen data-integrity audits [9,19].

Applicability to Academic and Investigator-Initiated Sponsors: Although this initiative was implemented within an industry sponsor context, the underlying principles of standardized subject identification—namely uniqueness, longitudinal traceability, and alignment with regulatory data standards—are equally relevant to academic and investigator-initiated trials. Academic sponsors may operate with different infrastructure and governance constraints; however, adoption of consistent identifier conventions, even at smaller scale, can reduce subject fragmentation across protocols and support data integration, collaboration, and regulatory submissions in multi-center or sponsor–academic partnership studies.

4.4. Limitations and future directions

Despite broad adoption, a few legacy studies still employ the older schema because of technical constraints in historical databases [11]. Future integration efforts may focus on automating the central-registry process through direct API connections with CTMS and EDC systems, reducing manual dependency and improving longitudinal interoperability across systems. These transition pathways are conceptual and reflect potential future enhancements rather than current implementation.

While the current master-Excel registry has proven effective, it is essentially a controlled manual tool. Transitioning to an enterprise-level metadata repository or a governed data-standards platform would further reduce risk and enable dynamic version control. While the subject identifier schema itself is technology-agnostic, the operational implementation described here relies on sponsor-specific infrastructure, and alternative technical architectures could be used while preserving the core design principles.Another prospective enhancement involves collaboration with CDISC and PhUSE to formalize the schema's structural attributes into an open data standard for industry-wide use [9,20]. Such harmonization could promote interoperability among sponsors, regulators, and technology vendors, thereby strengthening global data-exchange reliability.

Considerations for Decentralized and Hybrid Trial Models: Decentralized and hybrid clinical trial designs may introduce additional considerations for standardized subject identifier schemas. In such models, traditional site constructs may be virtual or distributed across multiple service providers, potentially complicating the use of site-based identifier components. While the core principles of subject uniqueness and longitudinal traceability remain applicable, decentralized settings may require adaptation of site-related elements or alternative governance mechanisms to ensure consistent identifier assignment across enrollment pathways, home health providers, and digital platforms. Future work may explore how standardized subject identification frameworks can be optimized to support increasingly decentralized trial architectures.

Risk Mitigation and Residual Design Trade-Offs: Potential risks associated with structured subject identifier design—including identifier length, system character limits, and usability at the site level—were assessed during schema development through cross-functional review and pre-implementation validation with sites, CROs, and system vendors (Section 2.4). These evaluations did not identify material limitations at the time of deployment. Nevertheless, as with any standardized approach, residual risk remains, particularly related to process execution and governance over time. In particular, reliance on a centralized, Excel-based registry for identifier assignment introduces a potential single point of failure and risk of human error, underscoring the importance of defined governance, oversight, and future opportunities for increased automation as the approach scales.

Change Management, Portfolio Evolution, and Privacy Considerations: As clinical programs and portfolios evolve, additional considerations may arise. Changes in program structure, study phase designation, or protocol amendments may result in divergence between encoded identifier attributes and current study metadata. Similarly, portfolio changes resulting from mergers or acquisitions may require harmonization across differing subject identifier conventions. These scenarios are managed through governance processes that preserve subject identifiers as stable references while allowing associated metadata to be updated without reassigning identifiers. Finally, although subject identifiers are pseudonymized and do not contain directly identifiable information, ongoing assessment of re-identification risk remains important to ensure alignment with privacy and data protection expectations as data integration and linkage increase.

Analytical Scope Limitations: Tokenization approaches and bucket-based trial grouping strategies were not explicitly considered or implemented as part of the subject identifier schema design or during initial implementation. Future work may assess whether such approaches could further enhance cross-study subject traceability. Sponsor may involve a third party to generate tokens, which can be mapped to the study-specific patient number (subject ID).

4.5. Practical implications

The standardized subject-ID schema delivers several tangible benefits:

• 1.Data Integrity: Unambiguous subject traceability across trials and phases.
• 2.Operational Efficiency: Reduced data-reconciliation workload and error rates.
• 3.Regulatory Readiness: Immediate alignment with global data-submission frameworks.
• 4.Future Scalability: The schema is agnostic to unique company processes, preventing it from becoming unusable in the future. Continues to meet business needs.

These outcomes validate the schema as a sustainable and scalable framework for ensuring data reliability in complex clinical portfolios. Its design can serve as a blueprint for industry adoption and contribute to the modernization of data standards ecosystems.

5. Conclusion

The transition from a legacy subject-identification (ID) framework to a portfolio-wide standardized schema (SSSS-PYZ-XXXA) has demonstrated measurable advancements in data integrity, operational efficiency, and regulatory compliance across global clinical-trial portfolios. By addressing long-standing issues of duplication, fragmented subject histories, and inconsistent identifier practices, the new schema strengthens the foundational reliability of trial data and enhances confidence in regulatory submissions [4,7,11,15].

As illustrated in Table 2, Table 3, the schema ensures complete subject traceability and uniformity across all systems while maintaining compatibility with established data standards such as the FDA Technical Conformance Guide and CDISC SDTM [1,2]. Through its encoded structure—linking site, program, phase, sequence, subject, and screening attempt—the model eliminates ambiguity and establishes a transparent chain of identification that aligns with ICH E6(R2) and EMA computerized-systems requirements [3,5].

Operationally, the introduction of a centralized master registry (Fig. 4) has enhanced inter-system synchronization and reduced manual reconciliation effort by more than 80 %, enabling a higher level of data governance and audit readiness [7,11,12]. The resulting regulatory outcomes—improved technical validation behavior, enhanced submission readiness, and improved SDTM mapping—highlight the schema's capacity to support complex, multinational submissions [14,15].

Looking ahead, the schema provides a scalable framework adaptable to evolving industry standards such as ICH M11, metadata-driven trial design, and automation of structured protocol data exchange [6,17,18,20]. Integration with enterprise data platforms and collaboration with standard-development bodies (CDISC, PhUSE, CTTI) will further expand its utility, potentially establishing it as a universal template for subject-identifier management across sponsors and regulatory regions [9,16,19,20].

Ultimately, this work demonstrates that consistent, standards-driven subject identification is not merely an operational convenience; it is a cornerstone of clinical-data reliability, ethical accountability, and regulatory transparency. The adoption of the SSSS-PYZ-XXXA schema offers a proven path toward harmonized, high-fidelity data ecosystems that accelerate trustworthy drug development and global health innovation.

CRediT authorship contribution statement

Ananya Jain: Writing – original draft, Visualization, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Steve Demas: Writing – review & editing, Validation, Methodology, Investigation, Formal analysis, Conceptualization. Todd Bazin: Writing – review & editing, Validation, Methodology, Investigation, Data curation, Conceptualization.

Declaration of competing interest

All authors are employees and shareholders of Biogen. The authors declare no other conflicts of interest related to this work. The Research and manuscript is funded by Biogen.

Data availability

The authors are unable or have chosen not to specify which data has been used.